ArticleJournal of animal science2025
All-trans retinoic acid protects piglets from TGEV-induced diarrhea and intestinal epithelial apoptosis by modulating redox status and endoplasmic reticulum stress pathways.
Article in Journal of animal science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bioinformatic Analyses of the Ataxin-2 Family Since Algae Emphasize Its Small Isoforms, Large Chimerisms, and the Importance of Human Exon 1B as Target of Therapies to Prevent Neurodegeneration.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transmissible gastroenteritis virus (TGEV) is a significant pathogen responsible for diarrhea in piglets, with its pathogenesis intricately associated with apoptosis. As a bioactive vitamin A derivative, all-trans retinoic acid (ATRA) possesses antiviral, antioxidant and anti-apoptotic characteristics. This research aimed to explore whether ATRA could mitigate TGEV infection in piglets through inhibition of intestinal epithelial apoptosis. In a 19-day trial, 32 piglets were randomized into four treatments: non-challenged group (Control), TGEV-challenged group (TGEV), TGEV+ 5 mg/d ATRA group (TGEV+ATRA5) and TGEV+ 15 mg/d ATRA group (TGEV+ATRA15). On day 15, piglets except the control group were challenged with TGEV. Results demonstrated that piglets administered with ATRA effectively prevented growth inhibition, diarrhea and intestinal impairment caused by TGEV, as confirmed by increased average daily gain, reduced diarrhea rate and diarrhea score, and upregulated villus height and tight-junction protein level (ZO-1 and Occludin) (P < 0.05). ATRA also markedly decreased TGEV RNA copies in the jejunum of TGEV-infected piglets (P < 0.05). Meanwhile, ATRA inhibited TGEV-induced intestinal epithelial apoptosis through inhibition of apoptosis-related protein expression (Bax, Fas, Caspase-9, -8, and -3) (P < 0.05). In addition, ATRA markedly attenuated TGEV-induced oxidative stress through reducing the production of hydrogen peroxide (H2O2) and malondialdehyde (MDA), while improving the activities of antioxidant enzymes (GSH-PX, SOD, and CAT) (P < 0.05). Further research found that ATRA also down-regulated the phosphorylation levels of P38MAPK and JNK, as well as the levels of apoptosis pathway-related proteins (GRP78, p-PERK, ATF6, and CHOP) mediated by endoplasmic reticulum stress (ERS) in jejunal mucosa of TGEV-infected piglets (P < 0.05). Our research demonstrated that ATRA could mitigate TGEV-triggered diarrhea and intestinal impairment of piglets by suppressing TGEV replication and intestinal epithelial apoptosis. The underlying mechanism by which ATRA inhibits intestinal epithelial apoptosis may be related to the suppression of oxidative stress-mediated P38MAPK/JNK pathways and ERS-mediated PERK/ATF6-CHOP pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.